{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:07:25Z","timestamp":1787652445545,"version":"build-2736575974"},"reference-count":301,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jncc.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T02:54:42Z","timestamp":1749783282000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Yujun","family":"Shuai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Network","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0003","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41588-022-01045-8","article-title":"HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer","volume":"54","author":"Lu","year":"2022","journal-title":"Nat Genet"},{"issue":"7765","key":"10.1016\/j.jncc.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0005","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5748","key":"10.1016\/j.jncc.2025.06.001_bib0007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrc3678","article-title":"Maintaining and reprogramming genomic androgen receptor activity in prostate cancer","volume":"14","author":"Mills","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"10.1016\/j.jncc.2025.06.001_bib0009","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/onc.2014.115","article-title":"Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects","volume":"34","author":"Ferraldeschi","year":"2015","journal-title":"Oncogene"},{"issue":"5928","key":"10.1016\/j.jncc.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0011","first-page":"314","article-title":"Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0013","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2015.109","article-title":"The oncogene ERG: a key factor in prostate cancer","volume":"35","author":"Adamo","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0014","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0015","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA methylation landscape of cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ccell.2016.03.007","article-title":"Exploiting the epigenome to control cancer-promoting gene-expression programs","volume":"29","author":"Brien","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0017","first-page":"158","article-title":"Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators","volume":"25","author":"Takahashi","year":"2023","journal-title":"Asian J Androl"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.06.001_bib0019","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ctrv.2017.03.008","article-title":"Epigenetic therapy and chemosensitization in solid malignancy","volume":"55","author":"Ronnekleiv-Kelly","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"10.1016\/j.jncc.2025.06.001_bib0020","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.3390\/cancers15225365","article-title":"Cancer epigenetic biomarkers","volume":"15","author":"Copped\u00e8","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0021","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","article-title":"The transcriptional and epigenetic landscape of cancer cell lineage plasticity","volume":"13","author":"Davies","year":"2023","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0023","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"issue":"6611","key":"10.1016\/j.jncc.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"issue":"6320","key":"10.1016\/j.jncc.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.jncc.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2002.10.018","article-title":"Molecular biology of the androgen receptor","volume":"20","author":"Gelmann","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1210\/mend-5-10-1396","article-title":"Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization","volume":"5","author":"Jenster","year":"1991","journal-title":"Mol Endocrinol"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0028","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cjp2.319","article-title":"Simone Chevalier. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression","volume":"9","author":"Seta Derderian","year":"2023","journal-title":"J Pathol Clin Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0032","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.urolonc.2008.03.021","article-title":"Mechanisms mediating androgen receptor reactivation after castration","volume":"27","author":"Yuan","year":"2009","journal-title":"Urol Oncol"},{"issue":"15","key":"10.1016\/j.jncc.2025.06.001_bib0033","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-08-2660","article-title":"Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer","volume":"15","author":"Knudsen","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0034","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000474453","article-title":"Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade","volume":"31","author":"Palmberg","year":"1997","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-023-00435-3","article-title":"Evolution of structural rearrangements in prostate cancer intracranial metastases","volume":"7","author":"Khani","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115312","article-title":"CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer","volume":"44","author":"Xiang","year":"2025","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0037","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1038\/s41467-022-35135-2","article-title":"Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential","volume":"13","author":"Kneppers","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0038","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1101\/gr.278418.123","article-title":"Chromatin interaction maps identify oncogenic targets of enhancer duplications in cancer","volume":"34","author":"Song","year":"2024","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0039","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/nar\/gkac1158","article-title":"Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","article-title":"Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex","volume":"28","author":"Heemers","year":"2007","journal-title":"Endocr Rev"},{"issue":"7406","key":"10.1016\/j.jncc.2025.06.001_bib0041","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0042","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/humu.20044","article-title":"The androgen receptor gene mutations database (ARDB): 2004 update","volume":"23","author":"Gottlieb","year":"2004","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0043","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/humu.22046","article-title":"The androgen receptor gene mutations database: 2012 update","volume":"33","author":"Gottlieb","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jncc.2025.06.001_bib0044","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijbiomac.2022.07.058","article-title":"Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients","volume":"218","author":"Khan","year":"2022","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0046","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/ijms23031557","article-title":"The T850D phosphomimetic mutation in the androgen receptor ligand binding domain enhances recruitment at activation function 2","volume":"23","author":"Helsen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0047","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0048","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146777","article-title":"Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth","volume":"131","author":"Nyquist","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0049","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41420-021-00764-x","article-title":"Androgen receptor regulates eIF5A2 expression and promotes prostate cancer metastasis via EMT","volume":"7","author":"Zheng","year":"2021","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0052","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.jncc.2025.06.001_bib0053","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Dehm","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0054","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jncc.2025.06.001_bib0056","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/0008-5472.CAN-24-0440","article-title":"LX1 Targets androgen receptor variants and AKR1C3 to overcome therapy resistance in advanced prostate cancer","volume":"84","author":"Ning","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.06.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100985","article-title":"Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells","volume":"70","author":"Wang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"19","key":"10.1016\/j.jncc.2025.06.001_bib0058","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","article-title":"Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis","volume":"83","author":"Sun","year":"2023","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0059","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0060","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3390\/cancers13122872","article-title":"CBP\/p300: critical Co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers","volume":"13","author":"Waddell","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0061","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0062","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.18632\/oncotarget.14401","article-title":"Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures","volume":"8","author":"Chattopadhyay","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.jncc.2025.06.001_bib0063","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/emboj.2011.328","article-title":"Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer","volume":"30","author":"Sahu","year":"2011","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0064","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","article-title":"Pioneer of prostate cancer: past, present and the future of FOXA1","volume":"12","author":"Teng","year":"2021","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/nar\/gkt921","article-title":"REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer","volume":"42","author":"Svensson","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0066","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1038\/s41467-023-40760-6","article-title":"Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance","volume":"14","author":"Rasool","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.06.001_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1190094","article-title":"Insights into the function of HDAC3 and NCoR1\/NCoR2 co-repressor complex in metabolic diseases","volume":"10","author":"Paluvai","year":"2023","journal-title":"Front Mol Biosci"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110109","article-title":"Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer","volume":"37","author":"Long","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jncc.2025.06.001_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116338","article-title":"Androgen receptor cofactors: a potential role in understanding prostate cancer","volume":"173","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5941","key":"10.1016\/j.jncc.2025.06.001_bib0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/306395a0","article-title":"A putative second cell-derived oncogene of the avian leukaemia retrovirus E26","volume":"306","author":"Leprince","year":"1983","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.jncc.2025.06.001_bib0071","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1073\/pnas.84.17.6131","article-title":"The erg gene: a human gene related to the ets oncogene","volume":"84","author":"Reddy","year":"1987","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4815","key":"10.1016\/j.jncc.2025.06.001_bib0072","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1126\/science.3299708","article-title":"erg, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation","volume":"237","author":"Rao","year":"1987","journal-title":"Science"},{"issue":"11\u201312","key":"10.1016\/j.jncc.2025.06.001_bib0073","article-title":"Lessons from Drosophila Pointed, an ETS family transcription factor and key nuclear effector of the RTK signaling pathway","volume":"56","author":"Vivekanand","year":"2018","journal-title":"Genesis"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0074","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/jpm11020138","article-title":"Gene Regulatory Network of ETS Domain transcription factors in different stages of glioma","volume":"11","author":"Babal","year":"2021","journal-title":"J Pers Med"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0075","first-page":"1751","article-title":"Characterization of the DNA binding and transcriptional activation domains of the erg protein","volume":"8","author":"Siddique","year":"1993","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0076","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/gcc.20329","article-title":"Confirmation of the high frequency of the TMPRSS2\/ERG fusion gene in prostate cancer","volume":"45","author":"Soller","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0077","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/modpathol.2009.193","article-title":"Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort","volume":"23","author":"Esgueva","year":"2010","journal-title":"Mod Pathol"},{"issue":"17","key":"10.1016\/j.jncc.2025.06.001_bib0078","doi-asserted-by":"crossref","first-page":"8347","DOI":"10.1158\/0008-5472.CAN-06-1966","article-title":"Expression of variant TMPRSS2\/ERG fusion messenger RNAs is associated with aggressive prostate cancer","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0079","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pros.24086","article-title":"TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer","volume":"81","author":"Yamoah","year":"2021","journal-title":"Prostate"},{"issue":"13","key":"10.1016\/j.jncc.2025.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/pros.24586","article-title":"Prostate cancer genetic alterations in Hispanic men","volume":"83","author":"Arenas-Gallo","year":"2023","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0081","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/MCB.26.3.965-975.2006","article-title":"Phenotypic analysis of mice lacking the Tmprss2-encoded protease","volume":"26","author":"Kim","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"17","key":"10.1016\/j.jncc.2025.06.001_bib0082","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/onc.2013.176","article-title":"Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2","volume":"33","author":"Tian","year":"2014","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0083","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ajpath.2013.11.007","article-title":"\u03b2III-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion","volume":"184","author":"Tsourlakis","year":"2014","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0084","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","article-title":"Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer","volume":"19","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molcel.2018.06.040","article-title":"Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis","volume":"71","author":"Sandoval","year":"2018","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0086","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1593\/neo.09572","article-title":"N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer","volume":"11","author":"Pflueger","year":"2009","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0087","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.celrep.2016.03.038","article-title":"Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer","volume":"15","author":"Zhao","year":"2016","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.jncc.2025.06.001_bib0088","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1242\/dev.01917","article-title":"Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation","volume":"132","author":"Gao","year":"2005","journal-title":"Development"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0089","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0090","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1158\/1078-0432.CCR-19-1669","article-title":"CDKN1B Deletions are associated with metastasis in African American men with clinically localized, surgically treated prostate cancer","volume":"26","author":"Faisal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7801","key":"10.1016\/j.jncc.2025.06.001_bib0091","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"issue":"7765","key":"10.1016\/j.jncc.2025.06.001_bib0092","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0093","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI122367","article-title":"Targeting FOXA1-mediated repression of TGF-\u03b2 signaling suppresses castration-resistant prostate cancer progression","volume":"129","author":"Song","year":"2019","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0094","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-12-3468","article-title":"Androgen receptor-independent function of FoxA1 in prostate cancer metastasis","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/djae224","article-title":"Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers","volume":"117","author":"Goglia","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0096","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0097","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrm1703","article-title":"Transcriptional regulation and transformation by Myc proteins","volume":"6","author":"Adhikary","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0098","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0099","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","article-title":"Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas","volume":"6","author":"Schaub","year":"2018","journal-title":"Cell Syst"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0100","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/1947601910379132","article-title":"MYC and prostate cancer","volume":"1","author":"Koh","year":"2010","journal-title":"Genes Cancer"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0101","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0102","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1530\/ERC-20-0517","article-title":"Novel insights in cell cycle dysregulation during prostate cancer progression","volume":"28","author":"Ben-Salem","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0103","doi-asserted-by":"crossref","first-page":"dju505","DOI":"10.1093\/jnci\/dju505","article-title":"Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis","volume":"107","author":"Kim","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0104","doi-asserted-by":"crossref","first-page":"L5","DOI":"10.1530\/ERC-21-0091","article-title":"Genomic alterations impact cell cycle-related genes during prostate cancer progression","volume":"28","author":"Ben-Salem","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/genes8020071","article-title":"Therapeutic approaches targeting MYC-driven prostate cancer","volume":"8","author":"Rebello","year":"2017","journal-title":"Genes (Basel)"},{"issue":"20","key":"10.1016\/j.jncc.2025.06.001_bib0106","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-12-2587","article-title":"Targeting cancer metabolism","volume":"18","author":"Teicher","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0107","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquera","year":"2013","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0109","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-019-0941-2","article-title":"N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway","volume":"18","author":"Yin","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jncc.2025.06.001_bib0111","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer","volume":"4","author":"Chalhoub","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0112","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0113","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41379-018-0107-6","article-title":"The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy","volume":"32","author":"Bramhecha","year":"2019","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0115","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/pros.23003","article-title":"A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer","volume":"75","author":"Troyer","year":"2015","journal-title":"Prostate"},{"issue":"14","key":"10.1016\/j.jncc.2025.06.001_bib0116","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175949","article-title":"Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts","volume":"134","author":"Zhang","year":"2024","journal-title":"J Clin Invest"},{"issue":"21","key":"10.1016\/j.jncc.2025.06.001_bib0117","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0960-9822(07)00488-5","article-title":"High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice","volume":"8","author":"Suzuki","year":"1998","journal-title":"Curr Biol"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0118","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0119","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/onc.2016.232","article-title":"Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer","volume":"36","author":"Su","year":"2017","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: new modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jncc.2025.06.001_bib0121","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-030-32656-2_14","article-title":"Interplay among PI3K\/AKT, PTEN\/FOXO and AR signaling in prostate cancer","volume":"1210","author":"Yan","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"Pt 15","key":"10.1016\/j.jncc.2025.06.001_bib0122","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1242\/jcs.001222","article-title":"Dynamic FoxO transcription factors","volume":"120","author":"Huang","year":"2007","journal-title":"J Cell Sci"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0123","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1158\/0008-5472.CAN-10-2603","article-title":"FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.jncc.2025.06.001_bib0124","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-17-0686","article-title":"Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.jncc.2025.06.001_bib0125","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1158\/0008-5472.CAN-08-2038","article-title":"A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0126","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/pros.22649","article-title":"FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants","volume":"73","author":"Bohrer","year":"2013","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0127","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10555-006-9032-0","article-title":"Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone","volume":"25","author":"Pratap","year":"2006","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0128","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/onc.2009.389","article-title":"Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions","volume":"29","author":"Akech","year":"2010","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2015.91","article-title":"Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease","volume":"35","author":"Ge","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0130","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/nar\/gkr1219","article-title":"Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion","volume":"40","author":"Little","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0131","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-13-2003","article-title":"Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness","volume":"74","author":"Little","year":"2014","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0132","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1476-4598-9-258","article-title":"Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis","volume":"23","author":"Baniwal","year":"2010","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0133","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jbmr.3869","article-title":"A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone","volume":"35","author":"Kim","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0134","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2015.91","article-title":"Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease","volume":"35","author":"Ge","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0135","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/1078-0432.CCR-17-2006","article-title":"PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6907","key":"10.1016\/j.jncc.2025.06.001_bib0136","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cance","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0137","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/0008-5472.CAN-15-2116","article-title":"An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells","volume":"76","author":"Peitzsch","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0138","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41388-022-02208-x","article-title":"Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer","volume":"41","author":"Yi","year":"2022","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0139","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ccell.2020.05.022","article-title":"SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways","volume":"38","author":"Yuan","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jb\/mvz097","article-title":"LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2","volume":"167","author":"Zhou","year":"2020","journal-title":"J Biochem"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0141","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14728222.2023.2293750","article-title":"miR-26a-5p restoration via EZH2 silencing blocks the IL-6\/STAT3 axis to repress the growth of prostate cancer","volume":"27","author":"Zhang","year":"2023","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0142","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep"},{"issue":"6113","key":"10.1016\/j.jncc.2025.06.001_bib0143","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0144","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jncc.2025.06.001_bib0145","article-title":"Safety profile of EZH2 inhibitors for cancer: a systematic review and meta-analysis","volume":"13","author":"Zhao","year":"2025","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0146","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13148-021-01045-1","article-title":"Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors","volume":"13","author":"Li","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0147","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"issue":"7057","key":"10.1016\/j.jncc.2025.06.001_bib0148","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0149","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/cancers11030324","article-title":"Expanding the role of the histone lysine-specific demethylase LSD1 in cancer","volume":"11","author":"Majello","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.jncc.2025.06.001_bib0150","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-17-0496","article-title":"LSD1-Mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression","volume":"77","author":"Liang","year":"2017","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.jncc.2025.06.001_bib0151","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167440","article-title":"LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function","volume":"8","author":"Kumaraswamy","year":"2023","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0152","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","article-title":"Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer","volume":"52","author":"Gao","year":"2020","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0153","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13148-017-0382-y","article-title":"LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer","volume":"11","author":"Battaglia","year":"2017","journal-title":"Clin Epigenetics"},{"issue":"18","key":"10.1016\/j.jncc.2025.06.001_bib0154","doi-asserted-by":"crossref","first-page":"E4179","DOI":"10.1073\/pnas.1719168115","article-title":"3rd AB, McWeeney SK. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function","volume":"115","author":"Sehrawat","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0155","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","article-title":"LSD1 Inhibition disrupts super-enhancer-driven oncogenic transcriptional programs in castration-resistant prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0156","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/epi-2017-0022","article-title":"A comprehensive review of lysine-specific demethylase 1 and its roles in cancer","volume":"9","author":"Hosseini","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.jncc.2025.06.001_bib0157","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials","volume":"14","author":"Noce","year":"2023","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0158","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S2352-3026(24)00132-7","article-title":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","volume":"11","author":"Salamero","year":"2024","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.jncc.2025.06.001_bib0159","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1002\/cncr.34366","article-title":"Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies","volume":"128","author":"Hollebecque","year":"2022","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jncc.2025.06.001_bib0160","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1007\/s00018-012-1254-4","article-title":"Transcriptional\/epigenetic regulator CBP\/p300 in tumorigenesis: structural and functional versatility in target recognition","volume":"70","author":"Wang","year":"2013","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0161","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1021\/acschembio.6b01035","article-title":"Identifying dysregulated epigenetic enzyme activity in castrate-resistant prostate cancer development","volume":"12","author":"Lee","year":"2017","journal-title":"ACS Chem Biol"},{"issue":"15","key":"10.1016\/j.jncc.2025.06.001_bib0162","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/0008-5472.CAN-20-0233","article-title":"p300-Mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.jncc.2025.06.001_bib0163","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","article-title":"p300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer","volume":"39","author":"Liu","year":"2020","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0164","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41419-024-06422-1","article-title":"Exploiting epigenetic targets to overcome taxane resistance in prostate cancer","volume":"15","author":"Cevatemre","year":"2024","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0165","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1021\/acs.jmedchem.3c01789","article-title":"Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP\/p300 PROTAC degrader for the treatment of advanced prostate cancer","volume":"67","author":"Chen","year":"2024","journal-title":"J Med Chem"},{"issue":"43","key":"10.1016\/j.jncc.2025.06.001_bib0166","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","article-title":"AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer","volume":"43","author":"Sardar","year":"2024","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0167","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acsmedchemlett.9b00227","article-title":"Systematically mitigating the p38\u03b1 activity of triazole-based BET inhibitors","volume":"10","author":"Carlson","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jncc.2025.06.001_bib0168","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.682696","article-title":"Regulation of carbohydrate-responsive metabolic genes by histone acetylation and the acetylated histone reader BRD4 in the gene body region","volume":"8","author":"Mochizuki","year":"2021","journal-title":"Front Mol Biosci."},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0169","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tibs.2015.06.002","article-title":"Beating the odds: bets in disease","volume":"40","author":"Wang","year":"2015","journal-title":"Trends Biochem Sci"},{"issue":"6400","key":"10.1016\/j.jncc.2025.06.001_bib0170","doi-asserted-by":"crossref","first-page":"eaar3958","DOI":"10.1126\/science.aar3958","article-title":"Coactivator condensation at super-enhancers links phase separation and gene control","volume":"361","author":"Sabari","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0171","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Xiangning Liu 1 LY. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discov"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114431","article-title":"Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0173","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 Promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0174","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0175","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1074\/mcp.RA119.001535","article-title":"Targeted and interactome proteomics revealed the role of PHD2 in regulating BRD4 proline hydroxylation","volume":"18","author":"Erber","year":"2019","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0176","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948795","article-title":"PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition","volume":"21","author":"Wang","year":"2020","journal-title":"EMBO Rep"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0177","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12808","article-title":"Role of BRD4 phosphorylation in the nucleus accumbens in relapse to cocaine-seeking behavior in mice","volume":"25","author":"Guo","year":"2020","journal-title":"Addict Biol"},{"issue":"22","key":"10.1016\/j.jncc.2025.06.001_bib0178","doi-asserted-by":"crossref","first-page":"eabf5374","DOI":"10.1126\/sciadv.abf5374","article-title":"BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation","volume":"7","author":"Vershinin","year":"2021","journal-title":"Sci Adv"},{"issue":"7327","key":"10.1016\/j.jncc.2025.06.001_bib0179","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"7327","key":"10.1016\/j.jncc.2025.06.001_bib0180","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"issue":"7570","key":"10.1016\/j.jncc.2025.06.001_bib0181","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"issue":"7570","key":"10.1016\/j.jncc.2025.06.001_bib0182","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0183","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0184","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.jncc.2025.06.001_bib0185","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1002\/j.1460-2075.1996.tb00921.x","article-title":"Purification and biochemical heterogeneity of the mammalian SWI-SNF complex","volume":"15","author":"Wang","year":"1996","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055119","article-title":"The spectrum of SWI\/SNF mutations, ubiquitous in human cancers","volume":"8","author":"Shain","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0187","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1097-2765(03)00039-X","article-title":"SWI\/SNF unwraps, slides, and rewraps the nucleosome","volume":"11","author":"Kassabov","year":"2003","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0188","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0189","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0190","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI123557","article-title":"Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer","volume":"129","author":"Ding","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0191","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1038\/s41467-022-34871-9","article-title":"ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"issue":"7893","key":"10.1016\/j.jncc.2025.06.001_bib0192","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"issue":"7414","key":"10.1016\/j.jncc.2025.06.001_bib0193","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","author":"Consortium","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0194","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0195","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41419-021-03854-x","article-title":"Role of noncoding RNA in drug resistance of prostate cancer","volume":"12","author":"Ding","year":"2021","journal-title":"Cell Death Dis"},{"issue":"464","key":"10.1016\/j.jncc.2025.06.001_bib0196","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.08.010","article-title":"Long non-coding RNAs in prostate cancer: functional roles and clinical implications","volume":"1","author":"Xu","year":"2019","journal-title":"Cancer Lett"},{"issue":"418","key":"10.1016\/j.jncc.2025.06.001_bib0197","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2018.01.012","article-title":"Prostate cancer-associated lncRNAs","volume":"1","author":"Mitobe","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jncc.2025.06.001_bib0198","doi-asserted-by":"crossref","first-page":"D145","DOI":"10.1093\/nar\/gkj084","article-title":"MODOMICS: a database of RNA modification pathways","volume":"34","author":"Dunin-Horkawicz","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0199","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","article-title":"Dynamic RNA modifications in gene expression regulation","volume":"169","author":"Roundtree","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0200","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1021\/bi00627a023","article-title":"Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid","volume":"16","author":"Wei","year":"1977","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0201","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.molmed.2023.03.005","article-title":"N6-methyladenosine-mediated gene regulation and therapeutic implications","volume":"29","author":"Liu","year":"2023","journal-title":"Trends Mol Med"},{"issue":"20","key":"10.1016\/j.jncc.2025.06.001_bib0202","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.3390\/cancers14205148","article-title":"The METTL3 RNA methyltransferase regulates transcriptional networks in prostate cancer","volume":"14","author":"Haigh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0203","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41419-023-05773-5","article-title":"Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0204","article-title":"Structural insights into the molecular mechanism of the m(6)A writer complex","volume":"14","author":"\u015aled\u017a","year":"2016","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nchembio.1432","article-title":"A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation","volume":"10","author":"Liu","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0206","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nchembio.687","article-title":"N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO","volume":"7","author":"Jia","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0207","first-page":"0313","article-title":"The FTO mediated N6-methyladenosine modification of DDIT4 regulation with tumorigenesis and metastasis in prostate cancer","volume":"21","author":"Zhao","year":"2024","journal-title":"Research (Wash D C)"},{"issue":"180","key":"10.1016\/j.jncc.2025.06.001_bib0208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.24976\/Discov.Med.202436180.5","article-title":"ALKBH5 Suppresses autophagy in prostate cancer cells via inhibiting m6A-modification of TSPAN1 mRNA","volume":"36","author":"Zhao","year":"2024","journal-title":"Discov Med"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0209","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.gastro.2023.04.032","article-title":"ALKBH5 Drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy","volume":"165","author":"Zhai","year":"2023","journal-title":"Gastroenterology"},{"issue":"14","key":"10.1016\/j.jncc.2025.06.001_bib0210","article-title":"N6-methyladenosine reader YTHDF family in biological processes: structures, roles, and mechanisms","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0211","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-020-01267-6","article-title":"YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0212","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1158\/0008-5472.CAN-23-1954","article-title":"m6A Modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB","volume":"84","author":"Shu","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0213","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.tips.2022.03.008","article-title":"Decoding pseudouridine: an emerging target for therapeutic development","volume":"43","author":"Cerneckis","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0214","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.molcel.2021.12.023","article-title":"Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing","volume":"82","author":"Martinez","year":"2022","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.urolonc.2020.06.026","article-title":"Pseudouridine as a novel biomarker in prostate cancer","volume":"39","author":"Stockert","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.jncc.2025.06.001_bib0216","article-title":"A five-pseudouridylation-associated-LncRNA classifier for primary prostate cancer prognosis prediction","volume":"10","author":"Zheng","year":"2023"},{"issue":"7679","key":"10.1016\/j.jncc.2025.06.001_bib0217","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature24456","article-title":"The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution","volume":"551","author":"Safra","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0218","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.cell.2009.02.003","article-title":"The dynamic landscapes of RNA architecture","volume":"136","author":"Cruz","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0219","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12964-023-01401-z","article-title":"Research progress of N1-methyladenosine RNA modification in cancer","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"Pt 2","key":"10.1016\/j.jncc.2025.06.001_bib0220","article-title":"N1-methyladenosine RNA methylation patterns are associated with an increased risk to biochemical recurrence in prostate cancer and serve as a potential novel biomarker for patient stratification","volume":"143","author":"Deng","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0221","article-title":"AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells","volume":"13","author":"Ueda","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0222","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/nar\/gkp1117","article-title":"5-methylcytosine in RNA: detection, enzymatic formation and biological functions","volume":"38","author":"Motorin","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0223","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13148-018-0540-x","article-title":"Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer","volume":"10","author":"Storebjerg","year":"2018","journal-title":"Clin Epigenetics"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0224","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.celrep.2013.06.029","article-title":"NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs","volume":"4","author":"Hussain","year":"2013","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0225","doi-asserted-by":"crossref","first-page":"e1028","DOI":"10.1002\/ctm2.1028","article-title":"Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression","volume":"12","author":"Zhu","year":"2022","journal-title":"Clin Transl Med"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0226","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.cell.2018.10.030","article-title":"Acetylation of cytidine in mRNA promotes translation efficiency","volume":"175","author":"Arango","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0227","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41392-021-00489-4","article-title":"NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0228","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/0008-5472.CAN-22-2233","article-title":"NAT10 Drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer","volume":"83","author":"Xie","year":"2023","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0229","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/cac2.12363","article-title":"N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA","volume":"42","author":"Zheng","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0230","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/nar\/gkv075","article-title":"Yeast Kre33 and human NAT10 are conserved 18S rRNA cytosine acetyltransferases that modify tRNAs assisted by the adaptor Tan1\/THUMPD1","volume":"43","author":"Sharma","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"32","key":"10.1016\/j.jncc.2025.06.001_bib0231","article-title":"NAT10 Promotes prostate cancer growth and metastasis by acetylating mRNAs of HMGA1 and KRT8","volume":"11","author":"Li","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0232","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","article-title":"The expanding regulatory mechanisms and cellular functions of circular RNAs","volume":"21","author":"Chen","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0233","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","article-title":"Widespread and functional RNA circularization in localized prostate cancer","volume":"176","author":"Chen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0234","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-021-01480-x","article-title":"Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p","volume":"21","author":"Yu","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13046-022-02381-7","article-title":"CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells","volume":"41","author":"Yu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0236","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13046-022-02404-3","article-title":"Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism","volume":"41","author":"Chen","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.06.001_bib0237","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ccell.2025.03.027","article-title":"Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation","volume":"43","author":"Teng","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0238","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13046-021-02138-8","article-title":"Hsa_circ_0004296 inhibits metastasis of prostate cancer by interacting with EIF4A3 to prevent nuclear export of ETS1 mRNA","volume":"40","author":"Mao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0239","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/15384101.2023.2174658","article-title":"circ_0063329 exerts its effect by sponging miR-605-5p to derepress TG-interacting factor 2 (TGIF2) and inactivate the TGF-\u03b2 pathway","volume":"22","author":"Lv","year":"2023","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112233","article-title":"Hsa_circ_0007494 suppresses prostate cancer progression via miR-616\/PTEN axis","volume":"395","author":"Zhang","year":"2020","journal-title":"Exp Cell Res"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0241","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","article-title":"Integrated lncRNA function upon genomic and epigenomic regulation","volume":"82","author":"Herman","year":"2022","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0242","article-title":"Dysregulation of the PRUNE2\/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts","volume":"16","author":"Lauer","year":"2023","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0243","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13046-023-02774-2","article-title":"LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a\/RREB1 positive feedback loop and a ceRNA network","volume":"42","author":"Dong","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0244","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ymthe.2017.04.016","article-title":"lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5","volume":"25","author":"Gu","year":"2017","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0245","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1093\/nar\/gkz108","article-title":"LncRNA PCAT1 activates AKT and NF-\u03bab signaling in castration-resistant prostate cancer by regulating the PHLPP\/FKBP51\/ikk\u03b1 complex","volume":"47","author":"Shang","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.jncc.2025.06.001_bib0246","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.molcel.2023.06.024","article-title":"A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling","volume":"83","author":"Zhang","year":"2023","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0247","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12943-019-1037-8","article-title":"A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer","volume":"18","author":"Gu","year":"2019","journal-title":"Mol Cancer"},{"issue":"19","key":"10.1016\/j.jncc.2025.06.001_bib0248","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1007\/s00018-019-03163-9","article-title":"Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer","volume":"76","author":"Vos","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"7006","key":"10.1016\/j.jncc.2025.06.001_bib0249","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0250","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.eururo.2015.12.054","article-title":"The potential of MicroRNAs as prostate cancer biomarkers","volume":"70","author":"Fabris","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0251","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-16-2529","article-title":"MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2","volume":"77","author":"Das","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0252","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/nar\/gkx1248","article-title":"A FTH1 gene:pseudogene:microRNA network regulates tumorigenesis in prostate cancer","volume":"46","author":"Chan","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"10.1016\/j.jncc.2025.06.001_bib0253","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.3390\/cancers14184538","article-title":"MicroRNA-34a, prostate cancer stem cells, and therapeutic development","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0254","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0255","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3390\/ijms25042123","article-title":"Developing folate-conjugated miR-34a therapeutic for prostate cancer: challenges and promises","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0256","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188809","article-title":"microRNA-205 in prostate cancer: overview to clinical translation","volume":"1877","author":"Chauhan","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0257","article-title":"MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes","volume":"23","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0258","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2014.09.005","article-title":"MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets","volume":"67","author":"Rane","year":"2015","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0259","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1021\/mp500099g","article-title":"MicroRNAs and drug resistance in prostate cancers","volume":"11","author":"Li","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jncc.2025.06.001_bib0260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.biopha.2018.01.088","article-title":"MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer","volume":"99","author":"Ma","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jncc.2025.06.001_bib0261","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.biopha.2017.10.040","article-title":"microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73","volume":"97","author":"Gao","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"7273","key":"10.1016\/j.jncc.2025.06.001_bib0262","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08533","article-title":"Forcing cells to change lineages","volume":"462","author":"Graf","year":"2009","journal-title":"Nature"},{"issue":"7467","key":"10.1016\/j.jncc.2025.06.001_bib0263","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.jncc.2025.06.001_bib0264","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jncc.2025.06.001_bib0265","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.jncc.2025.06.001_bib0266","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jncc.2025.06.001_bib0267","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0268","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12022-016-9421-z","article-title":"Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization classification","volume":"27","author":"Priemer","year":"2016","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0269","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clgc.2023.04.008","article-title":"Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: a multi-institutional study","volume":"21","author":"Eule","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"6320","key":"10.1016\/j.jncc.2025.06.001_bib0270","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jncc.2025.06.001_bib0271","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0272","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0273","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1038\/s41467-021-23780-y","article-title":"Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jncc.2025.06.001_bib0274","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","article-title":"The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression","volume":"36","author":"Su","year":"2019","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.jncc.2025.06.001_bib0276","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","article-title":"The genomic and epigenomic landscape of double-negative metastatic prostate cancer","volume":"83","author":"Lundberg","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0277","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110595","article-title":"Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis","volume":"39","author":"Han","year":"2022","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0278","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2025.06.001_bib0279","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/ijbs.41686","article-title":"Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways","volume":"16","author":"Lu","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0281","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41467-021-25175-5","article-title":"The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology","volume":"12","author":"Risbridger","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jncc.2025.06.001_bib0282","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1158\/1541-7786.MCR-14-0277-T","article-title":"p53 Mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma","volume":"13","author":"Li","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"16","key":"10.1016\/j.jncc.2025.06.001_bib0283","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","article-title":"Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.jncc.2025.06.001_bib0284","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1158\/0008-5472.CAN-03-2509","article-title":"Conditional deletion of Rb causes early stage prostate cancer","volume":"64","author":"Maddison","year":"2004","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.jncc.2025.06.001_bib0285","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-24-1388","article-title":"Neuroendocrine differentiation in prostate cancer requires ASCL1","volume":"84","author":"Rodarte","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0286","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41388-020-01526-2","article-title":"Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from pten null sca-1+ prostate luminal cells","volume":"40","author":"Kwon","year":"2021","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.jncc.2025.06.001_bib0287","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","article-title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1","volume":"5","author":"Romero","year":"2024","journal-title":"Nat Cancer"},{"issue":"18","key":"10.1016\/j.jncc.2025.06.001_bib0288","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179998","article-title":"BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity","volume":"134","author":"Westaby","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0289","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jncc.2025.06.001_bib0290","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1101\/gad.381706","article-title":"Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions","volume":"20","author":"Bracken","year":"2006","journal-title":"Genes Dev"},{"issue":"6","key":"10.1016\/j.jncc.2025.06.001_bib0291","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.cell.2016.04.031","article-title":"Acquired tissue-specific promoter bivalency is a basis for PRC2 necessity in adult cells","volume":"165","author":"Jadhav","year":"2016","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.06.001_bib0292","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","article-title":"A bivalent chromatin structure marks key developmental genes in embryonic stem cells","volume":"125","author":"Bernstein","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0293","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0294","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1038\/s41467-024-53874-2","article-title":"Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer","volume":"15","author":"Chatterjee","year":"2024","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.jncc.2025.06.001_bib0295","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167440","article-title":"LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function","volume":"8","author":"Kumaraswamy","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jncc.2025.06.001_bib0296","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101151","article-title":"LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer","volume":"63","author":"Kumaraswamy","year":"2025","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.jncc.2025.06.001_bib0297","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jncc.2025.06.001_bib0298","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","article-title":"ZNF397 Deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.jncc.2025.06.001_bib0299","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1093\/nar\/gkae547","article-title":"ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer","volume":"52","author":"Qian","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.jncc.2025.06.001_bib0300","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1093\/nar\/gkae206","article-title":"SIX2 promotes cell plasticity via wnt\/\u03b2-catenin signalling in androgen receptor independent prostate cancer","volume":"52","author":"Lepp\u00e4nen","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.jncc.2025.06.001_bib0301","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175217","article-title":"Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer","volume":"134","author":"Ku","year":"2024","journal-title":"J Clin Invest"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:29:26Z","timestamp":1771331366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266700542500064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":301,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S266700542500064X"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.06.001","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}